An investigative deep-dive for commercial leads, market access directors, and C-suite executives who negotiate with OptumRx, Express Scripts, and CVS […]
PBMs, Formularies, and Rebates: The Pharma Executive’s Survival Guide Read Post »
Every week, a medicinal chemistry team somewhere identifies a promising compound, runs it past the IP group, and asks a
Should You File a Provisional Patent for Your Drug Invention? The Honest Answer Read Post »
Every procurement director who has watched a blockbuster drug lose market exclusivity knows the same thing in hindsight: the scramble
The 180-day generic drug exclusivity period is, by raw financial math, one of the most lucrative regulatory prizes in the
Win the 180-Day FDA Exclusivity Race: Legal, Regulatory, and Commercial Playbook Read Post »
Mark Cuban launched Cost Plus Drugs in January 2022 with a simple premise: buy generic drugs at manufacturer cost, add
The PBM Endgame: What Mark Cuban Got Right (and Pharma Is Still Ignoring) Read Post »
A billionaire’s drugstore startup exposed the $6 billion arbitrage game inside America’s pharmacy benefit system. Now the entire supply chain
Mark Cuban’s Cost Plus Drugs Is Killing Spread Pricing — Here’s What That Actually Means Read Post »
Mark Cuban built his fortune by spotting inefficient markets and charging in with a simpler model. The Dallas Mavericks. HDNet.
In January 2022, Mark Cuban launched a pharmacy that listed drug prices on a public website. That alone was unusual.
How Cost Plus Drugs Exposes Drug Pricing Secrets Your Competitors Don’t Want You to Know Read Post »
Mark Cuban built a $5.8 billion fortune buying and selling assets that others undervalued. In January 2022, he turned that
Mark Cuban’s Generic Drug Play: Who Gets Disrupted First? Read Post »
Sign in or create a free account to read this DrugPatentWatch article
